• Oncology (+21.2%) and Diagnostics (+5.9%) lead Atrys’ growth and strengthen its position in precision medicine

• During the first nine months of 2025, the company inaugurated the Institute of Advanced Oncology (IOA) Madrid and opened two new medical oncology centres in Mexico

• The funds obtained from thesale of ASPY will be used to reduce the Group’s financial debtto bring the debt ratio to around 1.0x(from 3.7x), with annual savings in financial expenses of around €13million  

Atrys, a global healthtech company providing precision medical diagnosis and treatment services, a leader in telemedicine and cancer treatment, has announced its results for the third quarter of 2025, reflecting solid overall growth in turnover and consolidation in its key business areas: Oncology and Diagnostics.

During the first nine months of the year, the company increased its revenue by 8.2% compared to the same period in 2024, reaching 168.4 million euros. This growth is mainly supported by the positive performance of its most strategic business lines.

The gross margin on turnover stands at 62.5%, slightly below the 66% recorded in the same period last year, due to the greater weight of the Oncology and Diagnostics areas in the company’s overall turnover.

Adjusted EBITDA fell by 10.5% to €27.9 million, mainly due to the reduction in revenue from R&D project grants, which fell from €4.5 million in 2024 to €0.3 million this year. Excluding the impact of the reduction in revenue from R&D project grants, adjusted EBITDA increased by +3.5%.

During the first nine months of 2025, the company inaugurated the Institute of Advanced Oncology (IOA) in Madrid and opened two new medical oncology centres in Mexico.

Adjusted operating cash flow fell by 20.2% to £18.5 million, due to the combined effect of lower grant income and increased CAPEX for the opening of new centres. Without these effects, operating cash flow would have increased by 15.2%.

Oncology recorded growth of 21.2% and Diagnostics 5.9%, with a notable boost from the Genetics área

The company’s results for the first nine months of 2024 reflect positive performance in all business areas, with a notable boost from the Oncology segment, whose turnover grew by 21.2% to €55.254 billion. This growth was particularly strong in Mexico, with an increase of 63.1% thanks to the opening of new oncology centres, and in Spain, with 21.6%, driven by the excellent ramp-up of the IOA Madrid radiotherapy centre and high demand for the Medical Oncology service.

The Diagnostics area, meanwhile, grew by 5.9% to €51.492 billion. In this segment, the Pathology and Genetics Laboratories area stood out, experiencing growth of 19.3% due to strong demand for HPV tests in the Genetics area, which saw a notable increase in revenue of 111.9%.

The sale of ASPY significantly improves the Group’s debt and reinforces its core business strategy

On 4 November, Atrys announced the agreement to sell ASPY to Grupo Echevarne for €145 million, subject to regulatory approval and the approval of the General Shareholders’ Meeting, which will take place on 19 December. The funds obtained will be used to reduce the Group’s financial debt to bring the debt ratio (Net Financial Debt/Adjusted EBITDA) to around 1.0x (from 3.7x), with annual savings in financial expenses of around €13 million. Excluding the prevention area (ASPY) from the Atrys Group’s scope, pro forma LTM turnover will amount to €142.6 million and the Group’s adjusted EBITDA to €28.1 million. Pro forma organic growth in LTM turnover will increase from the current +8.2% to +13.4%. 

Marian Isach, CEO of the company, stated that “The sustained growth in our turnover reflects the strength of our strategic areas, Oncology and Diagnostics, which continue to consolidate their position as the core of our model. We are moving towards becoming a more agile, specialised company with an increasingly solid international presence, especially in Latin America. The divestment of ASPY will allow us to focus our resources on businesses with greater potential, drive innovation and generate greater value for our customers and shareholders”.